

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8041698

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
VALO HEALTH, LLC	06/30/2023
VALO HEALTH, INC.	06/30/2023

RECEIVING PARTY DATA

Name:	FIRST-CITIZENS BANK & TRUST COMPANY, AS AGENT
Street Address:	505 HOWARD STREET
Internal Address:	FLOOR 3
City:	SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94105

PROPERTY NUMBERS Total: 137

Property Type	Number
Patent Number:	8518958
Patent Number:	8232283
Patent Number:	8450348
Patent Number:	9555039
Patent Number:	11479564
Patent Number:	10272072
Patent Number:	10456382
Patent Number:	10772874
Patent Number:	11547701
Patent Number:	9676721
Patent Number:	10329275
Patent Number:	10647695
Patent Number:	11279687
Patent Number:	9169209
Patent Number:	9458172
Patent Number:	10696692
Patent Number:	9822129
Patent Number:	10730889

PATENT

Property Type	Number
Patent Number:	11485745
Patent Number:	10183934
Patent Number:	10407418
Patent Number:	10870645
Patent Number:	10214500
Patent Number:	10464909
Patent Number:	10442776
Patent Number:	10457652
Patent Number:	10464910
Patent Number:	10421732
Patent Number:	10988450
Patent Number:	9902728
Patent Number:	10377760
Patent Number:	10934299
Patent Number:	10000495
Patent Number:	10351571
Patent Number:	10981915
Patent Number:	9932351
Patent Number:	10377767
Patent Number:	10906916
Patent Number:	9938300
Patent Number:	10377773
Patent Number:	10927130
Patent Number:	9840491
Patent Number:	10513507
Patent Number:	10513508
Patent Number:	10519127
Patent Number:	10508098
Patent Number:	10519128
Patent Number:	10519129
Patent Number:	10519130
Patent Number:	10836741
Patent Number:	10029995
Patent Number:	10370343
Patent Number:	10829460
Patent Number:	11414392
Patent Number:	9630922
Patent Number:	10913753

Property Type	Number
Patent Number:	10239845
Patent Number:	10377726
Patent Number:	10479772
Patent Number:	10450284
Patent Number:	10472337
Patent Number:	10494353
Patent Number:	10829461
Patent Number:	11274084
Patent Number:	10214501
Patent Number:	10414738
Patent Number:	10428031
Patent Number:	10513501
Patent Number:	10829462
Patent Number:	10421731
Patent Number:	10450283
Patent Number:	11279681
Patent Number:	10112915
Patent Number:	10494351
Patent Number:	10494352
Patent Number:	10494354
Patent Number:	10822316
Patent Number:	10501424
Patent Number:	11274085
Patent Number:	10889592
Patent Number:	11325917
Patent Number:	9637453
Patent Number:	9745253
Patent Number:	10266487
Patent Number:	10508077
Patent Number:	10988441
Patent Number:	10508088
Patent Number:	10538496
Patent Number:	11345672
Patent Number:	10555935
Patent Number:	10874649
Patent Number:	11535607
Patent Number:	10800773
Patent Number:	11548886

Property Type	Number
Patent Number:	10865201
Patent Number:	7577553
Patent Number:	7194359
Patent Number:	7702467
Patent Number:	7856321
Application Number:	17941061
Application Number:	18073768
Application Number:	17124778
Application Number:	18196459
Application Number:	17238321
Application Number:	17186915
Application Number:	17230603
Application Number:	17161324
Application Number:	17179046
Application Number:	17096349
Application Number:	18096712
Application Number:	17691186
Application Number:	17238529
Application Number:	17712001
Application Number:	17130704
Application Number:	17984065
Application Number:	17959064
Application Number:	17121165
Application Number:	63394110
Application Number:	16952267
Application Number:	63482630
Application Number:	63457574
Application Number:	63429797
Application Number:	63466105
Application Number:	63423093
Application Number:	63350366
Application Number:	63422218
Application Number:	63401465
Application Number:	63417904
Application Number:	63482827
Application Number:	63429775
PCT Number:	US2021016317
PCT Number:	US2020018680

Property Type	Number
PCT Number:	US2019045734
PCT Number:	US2019045732
PCT Number:	US2020030833
PCT Number:	US2020031214
PCT Number:	US2020031608

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (619) 699-2708
Email: christian.cruz@us.dlapiper.com
Correspondent Name: DLA PIPER LLP (US)
Address Line 1: 4365 EXECUTIVE DRIVE
Address Line 2: SUITE 1100
Address Line 4: SAN DIEGO, CALIFORNIA 92121

NAME OF SUBMITTER:	MATT SCHWARTZ
SIGNATURE:	/s/ Matt Schwartz
DATE SIGNED:	07/06/2023

Total Attachments: 11
source=SVB-Valo Health- Amended and Restated IPSA (6.2023)#page1.tif
source=SVB-Valo Health- Amended and Restated IPSA (6.2023)#page2.tif
source=SVB-Valo Health- Amended and Restated IPSA (6.2023)#page3.tif
source=SVB-Valo Health- Amended and Restated IPSA (6.2023)#page4.tif
source=SVB-Valo Health- Amended and Restated IPSA (6.2023)#page5.tif
source=SVB-Valo Health- Amended and Restated IPSA (6.2023)#page6.tif
source=SVB-Valo Health- Amended and Restated IPSA (6.2023)#page7.tif
source=SVB-Valo Health- Amended and Restated IPSA (6.2023)#page8.tif
source=SVB-Valo Health- Amended and Restated IPSA (6.2023)#page9.tif
source=SVB-Valo Health- Amended and Restated IPSA (6.2023)#page10.tif
source=SVB-Valo Health- Amended and Restated IPSA (6.2023)#page11.tif

AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Amended and Restated Intellectual Property Security Agreement (“this Agreement”) dated as of June 30, 2023 is made by and among (a) **SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY** (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)) (“SVB”), in its capacity as administrative agent and collateral agent (in such capacity, “Agent”), (b) **VALO HEALTH, LLC**, a Delaware limited liability company (f/k/a INTEGRAL HEALTH HOLDINGS, LLC) (“Parent”), as a Guarantor, and (c) **VALO HEALTH, INC.**, a Delaware corporation (f/k/a INTEGRAL HEALTH, INC.) (“Opco”) (Parent, Opco and each such Qualified Subsidiary, individually and collectively, jointly and severally, “Grantor”) in connection with (x) that certain Loan and Security Agreement dated as of June 15, 2020 (as the same may be amended, modified or supplemented from time to time, including without limitation by that certain First Amendment to Loan and Security Agreement dated as of December 7, 2020, that certain Consent and Second Amendment to Loan and Security Agreement dated as of December 31, 2020, that certain Third Amendment to Loan and Security Agreement dated as of February 1, 2021, that certain Fourth Amendment to Loan and Security Agreement dated as of February 19, 2021, and that certain Default Waiver and Fifth Amendment to Loan and Security Agreement dated as of the date hereof, collectively, the “Loan Agreement”) by and among Grantor, Agent, SVB in its capacity as a Lender, and HERCULES CAPITAL, INC., a Maryland corporation in its capacity as a Lender thereunder (“Hercules” and together with SVB, the “Lenders”), and (ii) that certain Unconditional Secured Guaranty and Pledge Agreement dated as of June 15, 2020 (as the same may be amended, modified or supplemented from time to time, the “Parent Guaranty”) entered into by Parent in favor of Agent and the Lenders. This Agreement amends, restates, and supersedes in its entirety (a) that certain Intellectual Property Security Agreement dated as of June 15, 2020 by and between Parent and Agent, and (b) that certain Intellectual Property Security Agreement dated as of June 15, 2020 by and between Opco and Agent. Capitalized terms used but not defined herein, shall bear the meanings ascribed to such terms in the Loan Agreement.

RECITALS

A. The Lenders are willing to make loans to Borrower, but only upon the condition, among others, that Grantor shall grant to Agent, for the ratable benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the Obligations of Grantor.

B. Pursuant to the terms of the Loan Agreement and the Parent Guaranty, Grantor has granted to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of Grantor’s Obligations, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. To secure Grantor’s Obligations, Grantor grants and pledges to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its Intellectual Property (all of which shall collectively be called the “Intellectual Property Collateral”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “Copyrights”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, now or hereafter existing, created, acquired or held, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “Patents”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit B attached hereto (collectively, the “Trademarks”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit C attached hereto (collectively, the “Mask Works”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding anything to the contrary herein, the Intellectual Property Collateral shall not include any Intellectual Property associated with clinical and preclinical therapeutic assets of any Loan Party (“Excluded Intellectual Property”); provided, however, the Collateral shall include all Accounts and all proceeds of all Intellectual Property (including the Excluded Intellectual Property). If a judicial authority (including a U.S. Bankruptcy Court) would hold that a security interest in the underlying Intellectual Property is necessary to have a security interest in such Accounts and such property that are proceeds of Intellectual Property, then the Collateral shall automatically, and effective as of the Effective Date, include the Excluded Intellectual Property to the extent necessary to permit perfection of Agent’s, for the ratable benefit of the Lenders, security interest in such Accounts and such other property of the Loan Parties that are proceeds of such Intellectual Property.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Agent.

3. Authorization. Grantor hereby authorizes Agent to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement, and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

4. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement and the Parent Guaranty, which are hereby incorporated by reference. The provisions of the Loan Agreement and the Parent Guaranty shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Agent with respect to the Intellectual Property Collateral are as provided by the Loan Agreement, Parent Guaranty, and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

5. Execution in Counterparts. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., "pdf" or "tif" format) shall be effective as delivery of a manually executed counterpart of this Agreement.

6. Successors and Assigns. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.

7. Governing Law. This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the laws of the United States and the State of California, without giving effect to any choice or conflict of law provision or rule (whether of the State of California or any other jurisdiction).

[Balance of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties have caused this Amended and Restated Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

Address:

Valo Health, Inc.
399 Boylston St., Suite 505
Boston, MA 02116
Attn: David Berry, CEO
Email: dberry@integraltx.com

c/o Valo Health, Inc.
399 Boylston St., Suite 505
Boston, MA 02116
Attn: David Berry, CEO
Email: dberry@integraltx.com

Address:

Silicon Valley Bank, a division of
First-Citizens Bank & Trust Company, as Agent
505 Howard Street, Floor 3
San Francisco, California 94105
Attn: Mr. Peter Sletteland
Email: PSletteland@svb.com

GRANTOR:

Valo Health, Inc. (f/k/a Integral Health, Inc.)

By: David A. Berry, M.D., Ph.D.

Name: David A. Berry, M.D., Ph.D.

Title: President and Chief Executive Officer

Valo Health, LLC (f/k/a Integral Health Holdings, LLC)

By: David A. Berry, M.D., Ph.D.

Name: David A. Berry, M.D., Ph.D.

Title: President and Chief Executive Officer

AGENT:

First-Citizens Bank & Trust Company
(successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank))

By: Peter Sletteland

Name: Peter Sletteland

Title: Vice President

[Signature Page to Amended and Restated Intellectual Property Security Agreement]

EXHIBIT A

Copyrights

Description

Registration/
Application
Number

Registration/
Application
Date

None

EXHIBIT B

Patents and Trademarks

Owners	Record name	Status	Module	Country	Classes	Application number	Application Date	Registration/Grant number	Reg. / Grant date
Valo Health, Inc.	PP100 [2,3,4] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS	Granted	Patent	United States of America	PT/US2007/054259	10-Oct-2007 8,518,938	16-Oct-2007 8,518,938		27-Aug-2013
Valo Health, Inc.	PIRINORIC	Granted	Patent	United States of America	PT/US2009/092359	23-Apr-2009 2,253,289	23-Apr-2009 2,253,289		31-Jul-2013
Valo Health, Inc.	DERIVATIVES OF SOUARCIC ACID WITH ANTI-PROLIFERATIVE ACTIVITY	Granted	Patent	Switzerland	04030966.1	23-Dec-2004 1,674,457	23-Dec-2004 1,674,457		03-Jun-2009
Valo Health, Inc.	DERIVATIVES OF SOUARCIC ACID WITH ANTI-PROLIFERATIVE ACTIVITY	Granted	Patent	Germany	04030966.1	23-Dec-2004 602004021404.3	23-Dec-2004 602004021404.3		03-Jun-2009
Valo Health, Inc.	DERIVATIVES OF SOUARCIC ACID WITH ANTI-PROLIFERATIVE ACTIVITY	Granted	Patent	Spain	04030966.1	23-Dec-2004 4030966	23-Dec-2004 4030966		03-Jun-2009
Valo Health, Inc.	DERIVATIVES OF SOUARCIC ACID WITH ANTI-PROLIFERATIVE ACTIVITY	Granted	Patent	France	04030966.1	23-Dec-2004 1,674,457	23-Dec-2004 1,674,457		03-Jun-2009
Valo Health, Inc.	DERIVATIVES OF SOUARCIC ACID WITH ANTI-PROLIFERATIVE ACTIVITY	Granted	Patent	United Kingdom	04030966.1	23-Dec-2004 1,674,457	23-Dec-2004 1,674,457		03-Jun-2009
Valo Health, Inc.	DERIVATIVES OF SOUARCIC ACID WITH ANTI-PROLIFERATIVE ACTIVITY	Granted	Patent	Ireland	04030966.1	23-Dec-2004 1,674,457	23-Dec-2004 1,674,457		03-Jun-2009
Valo Health, Inc.	DERIVATIVES OF SOUARCIC ACID WITH ANTI-PROLIFERATIVE ACTIVITY	Granted	Patent	Switzerland	04030966.1	23-Dec-2004 1,674,457	23-Dec-2004 1,674,457		03-Jun-2009
Valo Health, Inc.	PERFERINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDP	Granted	Patent	United States of America	11/708,799	21-Feb-2007 8,450,348	21-Feb-2007 8,450,348		28-May-2013
Valo Health, Inc.	PERFERINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDP	Granted	Patent	United States of America	PT/US2011/050303	02-Sep-2011 9,555,039	02-Sep-2011 9,555,039		26-Apr-2017
Valo Health, Inc.	PERFERINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDP	Granted	Patent	United States of America	PT/US2011/050303	02-Sep-2011 9,555,039	02-Sep-2011 9,555,039		31-Jan-2017
Valo Health, Inc.	PERFERINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDP	Granted	Patent	United States of America	17/022,906	16-Sep-2020 11,479,564	16-Sep-2020 11,479,564		25-Oct-2022
Valo Health, Inc.	PERFERINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDP	Granted	Patent	United States of America	17/941,061	09-Sep-2022	09-Sep-2022		
Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	Brazil	PT/US2011/050321	02-Sep-2011 86112013004773-9	02-Sep-2011 86112013004773-9		31-May-2022
Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	Malaysia	PT/US2011/050321	02-Sep-2011 MY-190351-A	02-Sep-2011 MY-190351-A		15-Apr-2022
Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	Peru	PT/US2011/050321	02-Sep-2011 8497	02-Sep-2011 8497		13-Oct-2017
Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Pending	Patent	Thailand	PT/US2011/050321	02-Sep-2011	02-Sep-2011		
Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	Venezuela	2012001370	02-Sep-2011	02-Sep-2011		
Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	United States of America	15/352,184	15-Nov-2016 10,272,072	15-Nov-2016 10,272,072		30-Apr-2019
Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	United States of America	16/212,360	06-Dec-2018 10,456,382	06-Dec-2018 10,456,382		29-Oct-2019
Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	United States of America	16/338,208	12-Aug-2019 10,772,874	12-Aug-2019 10,772,874		15-Sep-2020
Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	United States of America	17/038,796	13-Sep-2020 11,547,701	13-Sep-2020 11,547,701		30-Jan-2023
Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Pending	Patent	United States of America	18/073,768	02-Dec-2022	02-Dec-2022		
Valo Health, Inc.	GUANIDINE COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	Mexico	PT/US2011/050323	02-Sep-2011 342838	02-Sep-2011 342838		14-Oct-2016
Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	United States of America	PT/US2011/050323	02-Sep-2011 9,676,721	02-Sep-2011 9,676,721		13-Jun-2017
Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	Mexico	PT/US2011/050320	02-Sep-2011 342481	02-Sep-2011 342481		30-Sep-2016
Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	United States of America	16/026,378	14-Jun-2018 10,239,275	14-Jun-2018 10,239,275		25-Jun-2019
Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	United States of America	16/619,333	22-May-2019 10,647,695	22-May-2019 10,647,695		12-May-2020
Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	United States of America	16/824,885	20-Mar-2020 11,279,687	20-Mar-2020 11,279,687		22-Mar-2022
Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	United States of America	PT/US2011/050301	02-Sep-2011 9,169,209	02-Sep-2011 9,169,209		27-Oct-2015
Genentech, Inc., Valo Health, Inc.	PIRIBIDYL AND PIRIBIDONYL SULFOXIDE AND SULFONE DERIVATIVES	Granted	Patent	Spain	PT/US2011/050214	01-Mar-2013 2,820,078	01-Mar-2013 2,820,078		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	PIRIBIDYL AND PIRIBIDONYL SULFOXIDE AND SULFONE DERIVATIVES	Granted	Patent	United States of America	PT/US2011/050214	01-Mar-2013 2,820,078	01-Mar-2013 2,820,078		21-Dec-2016
Genentech, Inc., Valo Health, Inc.	PIRIBIDYL AND PIRIBIDONYL SULFOXIDE AND SULFONE DERIVATIVES	Granted	Patent	United States of America	PT/US2011/050214	01-Mar-2013 9,458,172	01-Mar-2013 9,458,172		04-Oct-2016
Genentech, Inc., Valo Health, Inc.	AMIDO BENZYL SULFONE AND SULFOXIDE DERIVATIVES	Granted	Patent	United States of America	PT/US2011/050213	01-Mar-2013 10,696,692	01-Mar-2013 10,696,692		30-Jun-2020
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Pending	Patent	Singapore	10221018945	01-Mar-2013	01-Mar-2013		
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Albania	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Austria	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Australia	PT/US2011/050216	01-Mar-2013 2013225533	01-Mar-2013 2013225533		16-Nov-2017
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Belgium	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Bulgaria	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Canada	PT/US2011/050216	01-Mar-2013 2,865,325	01-Mar-2013 2,865,325		21-May-2019
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Switzerland	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	China	PT/US2011/050216	01-Mar-2013 201310802409.9	01-Mar-2013 201310802409.9		09-Oct-2020
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Czech Republic	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Denmark	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Estonia	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Spain	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Finland	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	France	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	United Kingdom	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Greece	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Croatia	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Hungary	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Iceland	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Iceland	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Japan	PT/US2011/050216	01-Mar-2013 64047.17	01-Mar-2013 64047.17		21-Sep-2018
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Lithuania	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Lithuania	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Luxembourg	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Latvia	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Malta	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Malta	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Netherlands	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Norway	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Poland	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Portugal	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Romania	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Serbia	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Sweden	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Slovenia	PT/US2011/050216	01-Mar-2013 1,120,405050U	01-Mar-2013 1,120,405050U		29-Oct-2018
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Slovenia	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Slovakia	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	San Marino	PT/US2011/050216	01-Mar-2013 2,820,008	01-Mar-2013 2,820,008		14-Dec-2016
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	United States of America	PT/US2011/050216	01-Mar-2013 9,822,129	01-Mar-2013 9,822,129		29-Nov-2017
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	United States of America	15/936,086	26-Mar-2018 10,730,889	26-Mar-2018 10,730,889		04-Aug-2020
Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	United States of America	16/944,581	31-Jul-2020 11,488,745	31-Jul-2020 11,488,745		01-Nov-2022
Courier Therapeutics	ESPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY C	Pending	Patent	Hong Kong	6202265095.3	14-Jun-2022	14-Jun-2022		
Courier Therapeutics									

Owners	Record name	Status	Module	Country	Classes	Application number	Application Date	Registration/Grant number	Reg. / Grant date
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Australia		PCT/US2015/067831	29-Dec-2015	2015747170	25-Mar-2021
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Pending	Patent	India		PCT/US2015/067831	29-Dec-2015		
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Pending	Patent	Canada		PCT/US2015/067831	29-Dec-2015		
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Switzerland		PCT/US2015/067831	29-Dec-2015		06-Nov-2019
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	China		PCT/US2015/067831	29-Dec-2015	42.013590077002.3	17-Dec-2019
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Germany		PCT/US2015/067831	29-Dec-2015	3240791	06-Nov-2019
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Spain		PCT/US2015/067831	29-Dec-2015	3240791	06-Nov-2019
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	France		PCT/US2015/067831	29-Dec-2015	3240791	06-Nov-2019
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United Kingdom		PCT/US2015/067831	29-Dec-2015	3240791	06-Nov-2019
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Hong Kong		1810767.3	29-Dec-2015	1246284	04-Jun-2021
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	India		PCT/US2015/067831	29-Dec-2015	3240791	06-Nov-2019
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	India		PCT/US2015/067831	29-Dec-2015	354622	29-Dec-2020
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Italy		PCT/US2015/067831	29-Dec-2015	3240791	06-Nov-2019
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Japan		PCT/US2015/067831	29-Dec-2015	6649388	20-Jan-2020
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Korea (South)		PCT/US2015/067831	29-Dec-2015		06-Nov-2019
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Switzerland		PCT/US2015/067831	29-Dec-2015	3240791	06-Nov-2019
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Macao		I/00407.3	29-Dec-2015	I/00407.3	17-Jun-2020
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Mexico		PCT/US2015/067831	29-Dec-2015	373788	23-Mar-2020
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Netherlands		PCT/US2015/067831	29-Dec-2015	3240791	06-Nov-2019
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Pakistan		PCT/US2015/067831	29-Dec-2015		
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Singapore		PCT/US2015/067831	29-Dec-2015	11201704897Q	29-Dec-2021
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Taiwan		10410496	29-Dec-2015	10898436	11-Jul-2020
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		147982.127	29-Dec-2015	3905728	27-Feb-2018
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Venezuela		2015-001095	29-Dec-2015		
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Pending	Patent	South Africa		PCT/US2015/067831	29-Dec-2015		
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Pending	Patent	European Patent Office (EPO)		19207235.3	29-Dec-2015		
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Pending	Patent	Hong Kong		42200206559.3	29-Dec-2015		
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Pending	Patent	New Zealand		771524	29-Dec-2015		
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	Taiwan		109118957	28-Dec-2015	1770525	11-Jul-2022
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		15/874,163	18-Jan-2018	10,377,760	13-Aug-2019
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		16/517,149	19-Jul-2019	10,934,299	02-Mar-2021
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		17/186,915	20-Feb-2021		
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		24/982,131	29-Dec-2015	10,000,093	19-Mar-2018
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		15/988,790	24-May-2018	15,351,571	16-Jul-2019
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		16/449,599	24-Jun-2019	10,981,915	20-Apr-2021
Valo Health, Inc.	PIRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Pending	Patent	United States of America		17/230,603	14-Apr-2021		
Valo Health, Inc.	THENOPYRIDINE CARBOXYAMIDES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		15/225,583	04-Feb-2016	9392,351	03-Apr-2018
Valo Health, Inc.	THENOPYRIDINE CARBOXYAMIDES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		15/909,200	01-Mar-2018	10,377,767	13-Aug-2019
Valo Health, Inc.	THENOPYRIDINE CARBOXYAMIDES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		16/515,194	18-Jul-2019	10,906,916	02-Feb-2021
Valo Health, Inc.	THENOPYRIDINE CARBOXYAMIDES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Pending	Patent	United States of America		17/161,324	28-Jan-2021		
Valo Health, Inc.	ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDIN	Granted	Patent	United States of America		15/205,586	04-Feb-2016	9398,300	10-Apr-2018
Valo Health, Inc.	ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDIN	Granted	Patent	United States of America		15/997,007	18-Feb-2018	10,377,773	13-Aug-2019
Valo Health, Inc.	ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDIN	Granted	Patent	United States of America		16/515,281	18-Jul-2019	10,927,130	23-Feb-2021
Valo Health, Inc.	ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDIN	Pending	Patent	United States of America		17/179,046	08-Feb-2021		
Valo Health, Inc.	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		15/205,571	04-Feb-2016	9400,491	12-Dec-2017
Valo Health, Inc.	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		15/937,979	11-Dec-2017	10,523,507	24-Dec-2019
Valo Health, Inc.	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		16/179,061	02-Nov-2018	10,533,508	24-Dec-2019
Valo Health, Inc.	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		16/179,071	02-Nov-2018	10,519,127	24-Dec-2019
Valo Health, Inc.	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		16/179,099	02-Nov-2018	10,508,098	17-Dec-2019
Valo Health, Inc.	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		16/179,111	02-Nov-2018	10,519,218	31-Dec-2019
Valo Health, Inc.	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		16/179,117	02-Nov-2018	10,519,139	31-Dec-2019
Valo Health, Inc.	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		16/179,125	02-Nov-2018	10,533,130	31-Dec-2019
Valo Health, Inc.	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		16/694,500	25-Nov-2019	10,836,741	17-Nov-2020
Valo Health, Inc.	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted	Patent	United States of America		17/096,349	12-Nov-2020		
Valo Health, Inc.	(6,6) FUSED BICYCLIC HDAC8 INHIBITORS	Pending	Patent	Pakistan		53972016	02-Sep-2016		
Valo Health, Inc.	(6,6) FUSED BICYCLIC HDAC8 INHIBITORS	Granted	Patent	United States of America		15/258,817	02-Sep-2016	10,029,995	24-Jul-2018
Valo Health, Inc.	(6,6) FUSED BICYCLIC HDAC8 INHIBITORS	Pending	Patent	Venezuela		2016-000479	02-Sep-2016		
Valo Health, Inc.	(6,6) FUSED BICYCLIC HDAC8 INHIBITORS	Granted	Patent	United States of America		16/093,861	08-Jun-2018	10,370,343	06-Aug-2019
Valo Health, Inc.	(6,6) FUSED BICYCLIC HDAC8 INHIBITORS	Granted	Patent	United States of America		16/449,675	24-Jun-2019	10,839,460	10-Nov-2020
Valo Health, Inc.	(6,6) FUSED BICYCLIC HDAC8 INHIBITORS	Granted	Patent	United States of America		17/066,385	03-Oct-2020	11,414,992	16-Aug-2022
Valo Health, Inc.	(6,6) FUSED BICYCLIC HDAC8 INHIBITORS	Pending	Patent	United States of America		18/096,712	13-Jan-2023		
Valo Health, Inc.	5-PIRROLO-7-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS	Granted	Patent	United States of America		15/130,613	15-Apr-2016	9,630,922	25-Apr-2017
Valo Health, Inc.	THENOPYRIDINE CARBOXYAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	Canada		PCT/US2017/017691	13-Feb-2017		
Valo Health, Inc.	THENOPYRIDINE CARBOXYAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted	Patent	China		PCT/US2017/017691	13-Feb-2017	20,201780021667.1	14-Jun-2022
Valo Health, Inc.	THENOPYRIDINE CARBOXYAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted	Patent	Belgium		PCT/US2017/017691	13-Feb-2017	3414252	06-Jul-2022
Valo Health, Inc.	THENOPYRIDINE CARBOXYAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted	Patent	Belgium		PCT/US2017/017691	13-Feb-2017	3414252	06-Jul-2022
Valo Health, Inc.	THENOPYRIDINE CARBOXYAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted	Patent	Germany		PCT/US2017/017691	13-Feb-2017	602017059022.1	06-Jul-2022
Valo Health, Inc.	THENOPYRIDINE CARBOXYAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted	Patent	France		PCT/US2017/017691	13-Feb-2017	3414252	06-Jul-2022
Valo Health, Inc.	THENOPYRIDINE CARBOXYAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted	Patent	United Kingdom		PCT/US2017/017691	13-Feb-2017	3414252	06-Jul-2022
Valo Health, Inc.	THENOPYRIDINE CARBOXYAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted	Patent	Switzerland		PCT/US2017/017691	13-Feb-2017	3414252	06-Jul-2022
Valo Health, Inc.	THENOPYRIDINE CARBOXYAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted	Patent	United States of America		PCT/US2017/017691	13-Feb-2017	3414252	06-Jul-2022
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	Taiwan		10520340	13-Feb-2016	10,949,486	09-Feb-2020
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	United States of America		15/018,916	02-Feb-2016	10,949,485	08-Mar-2019
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	Australia		PCT/US2016/016200	02-Feb-2016	20162152431	25-Mar-2021
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Pending	Patent	Brazil		PCT/US2016/016200	02-Feb-2016		
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Pending	Patent	Canada		PCT/US2016/016200	02-Feb-2016		
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	China		PCT/US2016/016200	02-Feb-2016	20,201680020984.7	23-Oct-2021
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	Austria		16/03457.9	02-Feb-2016	11439858	20-Oct-2021
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	Belgium		16/03457.9	02-Feb-2016	3292116	20-Oct-2021
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	Switzerland		16/03457.9	02-Feb-2016	3292116	20-Oct-2021
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	United States of America		16/03457.9	02-Feb-2016	3292116	20-Oct-2021
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	Germany		16/03457.9	02-Feb-2016	6020160605078.9	20-Oct-2021
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	Denmark		16/03457.9	02-Feb-2016	3292116	20-Oct-2021
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	Spain		16/03457.9	02-Feb-2016	3292116	20-Oct-2021
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	Finland		16/03457.9	02-Feb-2016	3292116	20-Oct-2021
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	France		16/03457.9	02-Feb-2016	3292116	20-Oct-2021
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	United Kingdom		16/03457.9	02-Feb-2016	3292116	20-Oct-2021
Valo Health, Inc.	3-ARYL-4-AMINO-BICYCLIC [4,5,2] HYDROXAMIC ACIDS AS HDAC INH								

Owners	Record name	Status	Module	Country	Classes	Application number	Application Date	Registration/Grant number	Reg. / Grant date
Valo Health, Inc.	THENOPYRONE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted	Patent	Netherlands		PCT/US2017/037691	13-Feb-2017	3414231	16-Oct-2019
Valo Health, Inc.	THENOPYRONE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted	Patent	United States of America		PCT/US2017/037691	13-Feb-2017	10,988,992	12-Jun-2021
Valo Health, Inc.	THENOPYRONE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted	Patent	United States of America		17/003,356	26-Aug-2020	11,325,917	10-May-2022
Valo Health, Inc.	3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS	Granted	Patent	United States of America		15/130,603	15-Apr-2016	9,637,453	02-May-2017
Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS	Pending	Patent	Canada		PCT/US2016/022029	11-Mar-2016		
Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS	Pending	Patent	Costa Rica		PCT/US2016/022029	11-Mar-2016		
Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS	Pending	Patent	Korea (South)		PCT/US2016/022029	11-Mar-2016		
Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS	Pending	Patent	New Zealand		PCT/US2016/022029	11-Mar-2016		
Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS	Granted	Patent	United States of America		15/067,065	11-Mar-2016	9,745,253	29-Aug-2017
Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS	Pending	Patent	European Patent Office (EPO)		2118963.7	11-Mar-2016		
Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS	Pending	Patent	United States of America		42032061.02.5	11-Mar-2016		
Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS	Pending	Patent	New Zealand		773.21	11-Mar-2016		
Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS	Granted	Patent	United States of America		15/925,559	19-Mar-2018	10,266,487	23-Apr-2019
Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS	Granted	Patent	United States of America		16/387,937	18-Apr-2019	10,508,077	17-Dec-2019
Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS	Granted	Patent	United States of America		16/589,252	20-Nov-2019	10,988,441	27-Apr-2021
Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS	Pending	Patent	United States of America		17/358,929	23-Apr-2021		
Valo Health, Inc.	METHODS USING HDAC11 INHIBITORS	Granted	Patent	United States of America		16/102,207	28-Nov-2018	10,508,088	17-Dec-2019
H. Lee Moffitt Cancer Center and Research Institute	METHODS USING HDAC11 INHIBITORS	Granted	Patent	United States of America		16/202,210	28-Nov-2018	10,538,496	21-Jan-2020
Valo Health, Inc.	METHODS USING HDAC11 INHIBITORS	Granted	Patent	United States of America		16/588,469	19-Nov-2019	11,345,672	31-May-2022
Valo Health, Inc.	METHODS USING HDAC11 INHIBITORS	Pending	Patent	United States of America		17/122,001	01-Apr-2022		
Valo Health, Inc.	2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Granted	Patent	Belgium		PCT/US2017/037970	16-Jun-2017	3472131	19-Feb-2020
Valo Health, Inc.	2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Granted	Patent	Switzerland		PCT/US2017/037970	16-Jun-2017	3472131	19-Feb-2020
Valo Health, Inc.	2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Granted	Patent	Germany		PCT/US2017/037970	16-Jun-2017	3472131	19-Feb-2020
Valo Health, Inc.	2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Granted	Patent	France		PCT/US2017/037970	16-Jun-2017	3472131	19-Feb-2020
Valo Health, Inc.	2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Granted	Patent	United Kingdom		PCT/US2017/037970	16-Jun-2017	3472131	19-Feb-2020
Valo Health, Inc.	2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Granted	Patent	Ireland		PCT/US2017/037970	16-Jun-2017	3472131	19-Feb-2020
Valo Health, Inc.	2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Granted	Patent	Switzerland		PCT/US2017/037970	16-Jun-2017	3472131	19-Feb-2020
Valo Health, Inc.	2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Granted	Patent	Netherlands		PCT/US2017/037970	16-Jun-2017	3472131	19-Feb-2020
Valo Health, Inc.	2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Granted	Patent	United States of America		PCT/US2017/037970	16-Jun-2017	10,538,535	11-Feb-2020
Valo Health, Inc.	2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Granted	Patent	United States of America		16/719,332	18-Dec-2019	10,874,649	29-Dec-2020
Valo Health, Inc.	2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Pending	Patent	United States of America		17/130,704	22-Dec-2020		
Valo Health, Inc.	ISONDOLINES AS HDAC INHIBITORS	Pending	Patent	Australia		PCT/US2019/028026	18-Apr-2019		
Valo Health, Inc.	ISONDOLINES AS HDAC INHIBITORS	Pending	Patent	Canada		PCT/US2019/028026	18-Apr-2019		
Valo Health, Inc.	ISONDOLINES AS HDAC INHIBITORS	Pending	Patent	China		PCT/US2019/028026	18-Apr-2019		
Valo Health, Inc.	ISONDOLINES AS HDAC INHIBITORS	Pending	Patent	European Patent Office (EPO)		PCT/US2019/028026	18-Apr-2019		
Valo Health, Inc.	ISONDOLINES AS HDAC INHIBITORS	Pending	Patent	Israel		PCT/US2019/028026	18-Apr-2019		
Valo Health, Inc.	ISONDOLINES AS HDAC INHIBITORS	Pending	Patent	Japan		PCT/US2019/028026	18-Apr-2019		
Valo Health, Inc.	ISONDOLINES AS HDAC INHIBITORS	Pending	Patent	Mexico		PCT/US2019/028026	18-Apr-2019		
Valo Health, Inc.	ISONDOLINES AS HDAC INHIBITORS	Pending	Patent	New Zealand		PCT/US2019/028026	18-Apr-2019		24-Apr-2023
Valo Health, Inc.	ISONDOLINES AS HDAC INHIBITORS	Pending	Patent	United States of America		PCT/US2019/028026	18-Apr-2019		
Valo Health, Inc.	ISONDOLINES AS HDAC INHIBITORS	Pending	Patent	South Africa		PCT/US2019/028026	18-Apr-2019		27-Dec-2022
Valo Health, Inc.	ISONDOLINES AS HDAC INHIBITORS	Pending	Patent	United States of America		17/984,065	09-Nov-2022		
Valo Health, Inc.	ISONDOLINES AS HDAC INHIBITORS	Pending	Patent	Hong Kong		6202104611.7	08-Aug-2019		
Valo Health, Inc.	INHIBITING DEUBIQUITINASE USP25 AND USP28	Pending	Patent	China		PCT/US2019/045734	08-Aug-2019		
Valo Health, Inc.	INHIBITING DEUBIQUITINASE USP25 AND USP28	Pending	Patent	European Patent Office (EPO)		PCT/US2019/045734	08-Aug-2019		
Valo Health, Inc.	INHIBITING DEUBIQUITINASE USP25 AND USP28	Pending	Patent	Hong Kong		6202104289.7	23-Nov-2021		
Valo Health, Inc.	INHIBITING DEUBIQUITINASE USP25 AND USP28	Pending	Patent	United States of America		PCT/US2019/045734	08-Aug-2019		
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted	Patent	Australia		PCT/US2018/046061	09-Aug-2018	2018136204	27-Oct-2022
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	Canada		PCT/US2018/046061	09-Aug-2018		
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	European Patent Office (EPO)		PCT/US2018/046061	09-Aug-2018		
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	Hong Kong		6202020294.2	09-Aug-2018		
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	United States of America		PCT/US2018/046061	09-Aug-2018	11,524,966	13-Dec-2022
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	Australia		PCT/US2019/045732	08-Aug-2019		
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	Canada		PCT/US2019/045732	08-Aug-2019		
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	China		PCT/US2019/045732	08-Aug-2019		
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	European Patent Office (EPO)		PCT/US2019/045732	08-Aug-2019		
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	Hong Kong		6202102895.9	23-Nov-2021		
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	Israel		PCT/US2019/045732	08-Aug-2019		
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	Mexico		PCT/US2019/045732	08-Aug-2019		
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	New Zealand		PCT/US2019/045732	08-Aug-2019		
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	United States of America		PCT/US2019/045732	08-Aug-2019		
Valo Health, Inc.	INHIBITING USP36	Pending	Patent	China		PCT/US2020/030833	30-Apr-2020		
Valo Health, Inc., Valo Health, LLC	INHIBITING USP36	Pending	Patent	European Patent Office (EPO)		PCT/US2020/030833	30-Apr-2020		
Valo Health, Inc., Valo Health, LLC	INHIBITING USP36	Pending	Patent	Japan		PCT/US2020/030833	30-Apr-2020		
Valo Health, Inc., Valo Health, LLC	INHIBITING USP36	Pending	Patent	United States of America		PCT/US2020/030833	30-Apr-2020		
Valo Health, Inc., Valo Health, LLC	INHIBITING USP36	Pending	Patent	Hong Kong		6202209811.9	08-Sep-2022		
Valo Health, Inc., Valo Health, LLC	INHIBITING TRABID	Pending	Patent	United States of America		PCT/US2020/031214	02-May-2020		
Valo Health, Inc., Valo Health, LLC	INHIBITING USP19	Pending	Patent	Australia		PCT/US2020/031608	06-May-2020		
Valo Health, Inc., Valo Health, LLC	INHIBITING USP19	Pending	Patent	Canada		PCT/US2020/031608	06-May-2020		
Valo Health, Inc., Valo Health, LLC	INHIBITING USP19	Pending	Patent	China		PCT/US2020/031608	06-May-2020		
Valo Health, Inc., Valo Health, LLC	INHIBITING USP19	Pending	Patent	European Patent Office (EPO)		PCT/US2020/031608	06-May-2020		
Valo Health, Inc., Valo Health, LLC	INHIBITING USP19	Pending	Patent	Japan		PCT/US2020/031608	06-May-2020		
Valo Health, Inc., Valo Health, LLC	INHIBITING USP19	Pending	Patent	United States of America		PCT/US2020/031608	06-May-2020		
Valo Health, Inc., Valo Health, LLC	INHIBITING USP19	Pending	Patent	Hong Kong		6202029951.3	09-Sep-2022		
Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending	Patent	European Patent Office (EPO)		PCT/US2017/050956	11-Sep-2017		
Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending	Patent	Hong Kong		1912872.5	11-Sep-2017		
Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending	Patent	Canada		PCT/US2017/050956	11-Sep-2017		
Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Granted	Patent	China		PCT/US2017/050956	11-Sep-2017	201708068713.3	05-May-2022
Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending	Patent	India		PCT/US2017/050956	11-Sep-2017		
Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Granted	Patent	Japan		PCT/US2017/050956	11-Sep-2017	7086942	10-Jun-2022
Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending	Patent	Korea (South)		PCT/US2017/050956	11-Sep-2017		
Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Granted	Patent	United States of America		PCT/US2017/050956	11-Sep-2017	10,800,773	13-Oct-2020
Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Granted	Patent	United States of America		16/996,660	20-Aug-2020	11,548,886	30-Jan-2023
Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending	Patent	United States of America		17/559,064	03-Oct-2022		
Valo Health, Inc.	BI-CYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Granted	Patent	European Patent Office (EPO)		PCT/US2017/050964	11-Sep-2017	3509588	07-Jun-2023
Valo Health, Inc.	BI-CYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending	Patent	Hong Kong		19128730.9	11-Sep-2017		
Valo Health, Inc.	BI-CYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending	Patent	Canada		PCT/US2017/050964	11-Sep-2017		
Valo Health, Inc.	BI-CYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending	Patent	China		PCT/US2017/050964	11-Sep-2017		
Valo Health, Inc.	BI-CYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending	Patent	India		PCT/US2017/050964	11-Sep-2017		
Valo Health, Inc.	BI-CYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Granted	Patent	Japan		PCT/US2017/050964	11-Sep-2017	7065081	27-Apr-2022
Valo Health, Inc.	BI-CYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending	Patent	Korea (South)		PCT/US2017/050964	11-Sep-2017		
Valo Health, Inc.	BI-CYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Granted	Patent	United States of America		PCT/US2017/050964	11-Sep-2017	10,865,201	15-Dec-2020
Valo Health, Inc.	BI-CYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending	Patent	United States of America		17/121,166	14-Dec-2020		
Valo Health, Inc.	METHODS AND APPARATUS FOR MOLECULAR MECHANICS ANALYSIS OF MOLECULAR	Granted	Patent	United States of America		10/452,481	30-May-2003	7,577,553	18-Aug-2009
Valo Health, Inc.	ESTIMATING THE ACCURACY OF MOLECULAR PROPERTY MODELS AND PREDICTIONS	Granted	Patent	United States of America		11/172,216	29-Jun-2005	7,194,359	20-Mar-2007
Valo Health, Inc.	MOLECULAR PROPERTY MODELING USING RANKING	Granted	Patent	United States of America		11/172,215	29-Jun-2005	7,702,467	20-Apr-2010
Valo Health, Inc.	MODELING BIOLOGICAL EFFECTS OF MOLECULES USING MOLECULAR PROPERTY MODEL	Granted	Patent	United States of America		11/350,209	18-Dec-2005	7,856,321	21-Dec-2010
Valo Health, Inc.	PROCESS FOR PREPARING 6-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINONES AND INTERMEDIATE	Granted	Patent	United States of America		63/340,110	01-Aug-2022		
Milica Radisic, Valo Health, Inc., ZHANG BOYANA	MICROPHYSIOLOGICAL PLATFORM WITH EMBEDDED ELECTRODES FOR 3D TISSUE C	Pending	Patent	Australia		PCT/US2020/017195	07-Feb-2020		
Milica Radisic, Valo Health, Inc., ZHANG BOYANA	MICROPHYSIOLOGICAL PLATFORM WITH EMBEDDED ELECTRODES FOR 3D TISSUE C	Pending	Patent	Canada		PCT/US2020/017195	07-Feb-		

Owners	Record name	Status	Module	Country	Classes	Application number	Application Date	Registration/Grant Reg. / Grant date
Valo Health, Inc.	BIDWIRE	Registered	Trademark	United States of America	42	88309956	15-May-2019 6456701	14-Sep-2021
Valo Health, Inc.	NUMERATE	Registered	Trademark	United States of America	42	77621344	25-Nov-2008 3660448	28-Jul-2009
Valo Health, LLC	VALO (CIRCLE)	Pending	Trademark	United States of America	1, 5, 9, 42	8945793	03-Jun-2020	
Valo Health, LLC	VALO (CIRCLE)	Registered	Trademark	World Intellectual Property Org. (WIPO)	1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570658	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Pending	Trademark	Australia	1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570658	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Pending	Trademark	Canada	1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570658	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Registered	Trademark	Switzerland	1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570658	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Pending	Trademark	China	1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570658	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Registered	Trademark	European Union Intellectual Property Office (EUI)	1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570658	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Registered	Trademark	United Kingdom	1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570658	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Registered	Trademark	Israel	1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570658	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Pending	Trademark	Japan	1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570658	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Registered	Trademark	Singapore	1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570658	03-Dec-2020
Valo Health, LLC	VALO (COLOR)	Pending	Trademark	United States of America	1, 5, 9, 36, 42	8945991	03-Jun-2020	
Valo Health, LLC	VALO DATA GRAVITY	Registered	Trademark	World Intellectual Property Org. (WIPO)	42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Pending	Trademark	Australia	42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Pending	Trademark	Canada	42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Registered	Trademark	Switzerland	42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Registered	Trademark	China	42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Registered	Trademark	European Union Intellectual Property Office (EUI)	42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Registered	Trademark	United Kingdom	42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Registered	Trademark	Israel	42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Registered	Trademark	Japan	42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Pending	Trademark	Singapore	42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO HEALTH	Registered	Trademark	United States of America	1, 5, 9, 42	8945793	03-Jun-2020	
Valo Health, LLC	VALO HEALTH	Registered	Trademark	World Intellectual Property Org. (WIPO)	1, 5, 9, 36, 42	A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO HEALTH	Pending	Trademark	Australia	1, 5, 9, 36, 42	A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO HEALTH	Pending	Trademark	Canada	1, 5, 9, 36, 42	A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO HEALTH	Registered	Trademark	Switzerland	1, 5, 9, 36, 42	A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO HEALTH	Pending	Trademark	China	1, 5, 9, 36, 42	A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO HEALTH	Registered	Trademark	European Union Intellectual Property Office (EUI)	1, 5, 9, 36, 42	A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO HEALTH	Registered	Trademark	United Kingdom	1, 5, 9, 36, 42	A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO HEALTH	Registered	Trademark	Israel	1, 5, 9, 36, 42	A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO HEALTH	Registered	Trademark	Japan	1, 5, 9, 36, 42	A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO HEALTH	Registered	Trademark	Singapore	1, 5, 9, 36, 42	A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Pending	Trademark	United States of America	41	90181491	15-Sep-2020	
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Registered	Trademark	World Intellectual Property Org. (WIPO)	41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Pending	Trademark	Australia	41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Pending	Trademark	Canada	41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Registered	Trademark	Switzerland	41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Registered	Trademark	China	41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Registered	Trademark	European Union Intellectual Property Office (EUI)	41, 42	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Registered	Trademark	United Kingdom	41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Registered	Trademark	Israel	41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Registered	Trademark	Japan	41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Registered	Trademark	Singapore	41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO	Pending	Trademark	United States of America	1, 5, 9, 42	8945779	03-Jun-2020	
Valo Health, LLC	VALO	Registered	Trademark	World Intellectual Property Org. (WIPO)	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark	Australia	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark	Canada	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark	Switzerland	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark	China	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark	European Union Intellectual Property Office (EUI)	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark	United Kingdom	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark	Israel	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark	Japan	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark	Singapore	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020

EXHIBIT C

Mask Works

Description

Registration/
Application
Number

Registration/
Application
Date

None